具有抗肿瘤作用的三帖类衍生物TBA-X及其制备方法和应用
技术领域
本发明涉及一种化合物及其制备方法和应用,具体一种具有抗肿瘤活性的化合物及其制备方法和应用,属于药物化学领域。
背景技术
中国专利201110055102.X公开了抗癌先导化合物T-OA,药效学实验表明,先导物T-OA能较显著抑制多种肿瘤细胞的体外增殖,而对正常细胞毒性较低;体内对S180小鼠肉瘤的生长有显著抑制活性,并可提高荷瘤小鼠的脾指数,均呈剂量依赖关系。通过计算肿瘤横截面积,可以清晰观察到肿瘤体积、肿瘤横截面积比明显缩小,而毒副作用又显著低于环磷酰胺。对肿瘤凋亡NF-KB信号通路研究发现,T-OA给药后可以显著降低肉瘤小鼠P65、COX-2和VEGF的表达,并可抑制金属蛋白酶-2的活性;此外,T-OA还可明显抑制鸡胚尿囊膜新生血管增生,具有抗血管生成的作用。单日连续给予T-OA最大耐受量6000mg·kg-1,观察14天内,小鼠未出现毒性反应,优于环磷酰胺。
本发明以具有抗肿瘤、抗肝病生物活性的齐墩果酸(OA)、甘草次酸(GA)、熊果酸(UA)、白桦脂酸(BA)及天然药物川芎嗪(TMP)为起始原料,进行化学拼合合成本发明化合物。对该类化合物的活性评价主要围绕抗肿瘤(尤其肝癌)方面展开,分别测试了类似物对5种癌症细胞系(Bel-7402,HepG2,HT-29,Hela,MCF-7)和正常细胞系(MDCK)的细胞毒活性。
发明内容
本发明的目的之一是提供一种具有结构通式1的化合物。
本发明的目的之二是提供一种具有结构通式2的化合物。
本发明的目的之三是提供通式化合物1、2的制备方法。
本发明的目的之四是提供通式化合物1、2在制备抗肿瘤药物中的应用。
本发明的目的之五是提供一种具有抗肿瘤作用的药物组合物。
本发明的目的是通过如下技术方案实现的:
具有抗肿瘤作用的式1化合物,
式1
其中,
R1选自-OH、-X中的一种;
R2选自-H、=O中的一种;
R3、R4选自-H、-CH3中的一种;
R5、R6选自-CH3、-Y、-Z、-COOH中的一种;
且R1、R5、R6中至少有一个包含-X、-Y或-Z;
上述-X、-Y和-Z结构式如下:
具有抗肿瘤作用的式2化合物,
式2;
其中,R1选自-OH、-X中的一种;
R2选自-COOH、-Y、-Z中的一种;
且R1、R2中至少有一个包含-X、-Y或-Z;
上述-X、-Y和-Z结构式如下:
进一步,本发明化合物编号及结构式如下:
本发明化合物按如下方法制备:
化合物TBA-X1的制备方法:将齐墩果酸溶于有机溶剂,与溴代川芎嗪(化合物1)在碱性条件下生成TBA-X1;
化合物TBA-X2的制备方法:将熊果酸溶于有机溶剂,与溴代川芎嗪(化合物1)在碱性条件下生成TBA-X2;
化合物TBA-X3的制备方法:将甘草次酸溶于有机溶剂,与溴代川芎嗪(化合物1)在碱性条件下生成TBA-X3;
化合物TBA-X4的制备方法:将白桦脂酸溶于有机溶剂,与溴代川芎嗪(化合物1)在碱性条件下生成TBA-X4;
化合物TBA-X5的制备方法:将TBA-X1溶于有机溶剂,与川芎嗪酸(化合物2)在缩合剂、催化剂作用下生成TBA-X5;
化合物TBA-X6的制备方法:将TBA-X2溶于有机溶剂,与川芎嗪酸(化合物2)在缩合剂、催化剂作用下生成TBA-X6;
化合物TBA-X7的制备方法:将TBA-X3溶于有机溶剂,与川芎嗪酸(化合物2)在缩合剂、催化剂作用下生成TBA-X7;
化合物TBA-X8的制备方法:将TBA-X4溶于有机溶剂,与川芎嗪酸(化合物2)在缩合剂、催化剂作用下生成TBA-X8;
化合物TBA-X9的制备方法:将苄基保护的齐墩果酸(化合物4)溶于有机溶剂,与川芎嗪酸(化合物2)在缩合剂、催化剂作用下生成TBA-X9;
化合物TBA-X10的制备方法:将苄基保护的熊果酸(化合物5)溶于有机溶剂,与川芎嗪酸(化合物2)在缩合剂、催化剂作用下生成TBA-X10;
化合物TBA-X11的制备方法:将苄基保护的甘草次酸(化合物6)溶于有机溶剂,与川芎嗪酸(化合物2)在缩合剂、催化剂作用下生成TBA-X11;
化合物TBA-X12的制备方法:将苄基保护的白桦脂酸(化合物7)溶于有机溶剂,与川芎嗪酸(化合物2)在缩合剂、催化剂作用下生成TBA-X12;
化合物TBA-X13的制备方法:将TBA-X9溶于有机溶剂,在催化剂作用下生成TBA-X13;
化合物TBA-X14的制备方法:将TBA-X10溶于有机溶剂,在催化剂作用下生成TBA-X14;
化合物TBA-X15的制备方法:将TBA-X11溶于有机溶剂,在催化剂作用下生成TBA-X15;
化合物TBA-X16的制备方法:将TBA-X12溶于有机溶剂,在催化剂作用下生成TBA-X16;
其中,上述反应在-20℃至250℃下进行;所述有机溶剂是含有1-20个碳原子的醚、醇、烷烃、芳香烃、酮、卤代烷、酰胺、腈、酯或者它们各种比例的混合物;所述催化剂为4-二甲氨基吡啶(DMAP)、钯碳(Pd/C)和氢氧化钯碳(Pd(OH)2/C);所述缩合剂为1-乙基-3-(3-二甲胺丙基)碳二亚胺盐酸盐(EDCI)或1,3-二环己基碳二亚胺(DCC);此外,所用碱中,无机碱为碳酸钾。
进一步,上述制备方法中,相应的原料与溴代川芎嗪的摩尔比为1∶0.1~1∶10;相应的原料与缩合剂的摩尔比为1∶0.1~1∶10;相应的原料与碱的摩尔比为1∶0.1~1∶10;相应的原料与催化剂的摩尔比为1∶0.1~1∶10。
反应路线:
路线1、TBA-X1-4,TBA-X5-8的合成
反应条件和试剂:(a)Benzene,reflux,10h;(b)CCl4,NBS,hv,reflux,12h;(c)DMF,K2CO3,N2,85℃,1.5h;(d)H2O,KMnO4,37℃,6h;(e)dry CH2Cl2,EDCI,DMAP,12h.
路线2、TBA-X9-12,TBA-X13-16的合成
反应条件和试剂:(a)DMF,K2CO3,N2,85℃,1.5h;(b)dry CH2Cl2,EDCI,DMAP,12h;(c)MeOH,10%Pd/C或Pd(OH)2/C,H2,12h。
本发明还提供式1、2化合物在制备抗肿瘤药物中的应用。
进一步,所述肿瘤为肝癌、胃癌、结肠癌、宫颈癌细胞系。
本发明还提供了一种抗肿瘤的药物组合物,该组合物包含式1或式2化合物和药学上可接受的载体。所述药物组合物可以是片剂、胶囊剂、颗粒剂、散剂、口服液、注射剂等常规剂型。
本发明化合物具有明显抑制肿瘤细胞系(Bel-7402,HepG2,HT-29,Hela,MCF-7)生长的活性。其中,化合物TBA-X4的抗肿瘤活性优于阳性药顺铂。
实验例MTT法观察本发明组合物TBA-X对肿瘤细胞和正常细胞增殖影响
1.仪器与材料
Thermo 3111型CO2培养箱;HFsafe生物安全柜;Multiskan GO酶标仪;京立牌LD5-2B型台式低速离心机;Olympus IX71倒置荧光显微镜改良型RPMI-1640培养基、胎牛血清、0.25%胰蛋白酶溶液、噻唑蓝、磷酸盐缓冲液(赛默飞世尔生物化学制品北京有限公司);二甲基亚砜(DMSO);
人肝癌细胞系Bel-7402和HepG2;人胃癌细胞系BGC-823;人结肠癌细胞系HT-29;人宫颈癌细胞系Hela;犬肾上皮细胞MDCK。
实验药物:本发明化合物TBA-X1-16(分别按实施例8-21制备);反应原料齐墩果酸(OA)、甘草次酸(GA)、熊果酸(UA)、白桦脂酸(BA)及川芎嗪(TMP);阳性药物注射用顺铂(301001CF;齐鲁制药有限公司);
2.方法
2.1不同细胞株的培养
Bel-7402,HepG2,HT-29,MCF-7细胞培养在含10%胎牛血清的1640培养液中,放置于37℃、5%的CO2培养箱中温育。细胞均呈贴壁状态生长,在倒置显微镜下观察生长状况,待细胞数量适量时传代培养。
Hela,MDCK细胞培养在含10%胎牛血清的DMEM培养液中,放置于37℃、5%的CO2培养箱中温育。细胞均呈贴壁状态生长,在倒置显微镜下观察生长状况,待细胞数量适量时传代培养。
2.2初筛细胞抑制率
取对数生长期的Bel-7402,HepG2,HT-29,Hela,MCF-7,MDCK细胞,以3×103/孔的数量接种于96孔培养板中,在含5%CO2的湿化培养箱中37℃培养24h。每孔分别加入100μL待测化合物,使每孔浓度分别为10μM和20μM。设置细胞对照组及空白对照组,药物组每浓度重复3孔,细胞对照组和空白对照组重复3孔。培养箱中继续培养72h后,每孔加20μLMTT孵育4h,弃去上清,再加100μL DMSO,振荡10min,酶标仪490nm波长测得吸光度值并记录结果,抑制率/%=[1-(A给药-A空白)/(A正常-A空白)]×100%。将20μM浓度下,抑制率大于50%的化合物进行复筛并计算IC50值。
2.3复筛细胞抑制率
操作方法如2.2项,取对数生长期的Bel-7402,HepG2,HT-29,Hela,MCF-7,MDCK细胞,以3×103/孔的数量接种于96孔培养板中,在含5%CO2的湿化培养箱中37℃培养24h;每孔分别加入100μL待测化合物,使最终浓度分别为40,20,10,5,2.5μM。设置细胞对照组及空白对照组,药物组每浓度重复4孔,细胞对照组和空白对照组重复3孔。培养箱中继续培养72h后,每孔加20μL MTT孵育4h,弃去上清,再加100μL DMSO,振荡10min,酶标仪490nm波长测得吸光度值,记录结果,并计算化合物的IC50值,细胞抑制率(%)=[1-(A给药-A空白)/(A正常-A空白)]×100%。
3.结果
3.1本发明化合物TBA-X1-16和反应原料OA、GA、UA、BA及TMP对5种肿瘤细胞系(Bel-7402,HepG2,HT-29,Hela,MCF-7)和正常细胞系MDCK的IC50值如表1所示。
由表1可以看出,与反应原料相比,大部分化合物表现出更强的体外抗肿瘤活性;化合物TBA-X1,TBA-X4,TBA-X13和TBA-X16对各种癌细胞均表现出较好的抑制肿瘤细胞增殖活性,特别是化合物TBA-X4的体外抗肿瘤活性甚至优于顺铂;
化合物TBA-X2对肝癌细胞的增殖具有抑制作用,化合物TBA-X14对结肠癌细胞的增殖具有抑制作用,化合物TBA-X11对胃癌细胞增殖具有抑制作用。
表1不同药物对不同肿瘤细胞株的IC50值
注明:a:当IC50>20.0μM时,我们认为其活性较低;
b:“ND”表明未能测出IC50值。
4.结论
本发明化合物表现出抑制肿瘤细胞系(Bel-7402,HepG2,HT-29,Hela,MCF-7)增殖的活性。其中,化合物TBA-X4的活性优于阳性药顺铂。表明该类化合物可用于抗肿瘤药物的研究。
具体实施方式
实施例1中间体化合物1(2-溴代甲基-3,5,6-三甲基吡嗪)的制备
按“《中间体2-溴甲基-3,5,6-三甲基吡嗪的合成工艺优化》.安徽医药,2013,17(9):1467-1470”方法制备。称取20.00g(0.15mol)无水川芎嗪、23.54g N-溴代丁二酰亚胺(0.15mol,用前研细)置于250mL三颈瓶,100mL CCl4作为反应溶剂,4盏85W白炽灯照射,95℃回流反应1h。TLC[V(石油醚)∶V(丙酮)=3∶1]检测反应基本完全;冷却后滤过,收集滤液,减压回收溶剂,得紫红色粘稠状液体(含量按60%计)。HRMS(ESI)m/z:216.00135[M+H]+,calcd.for C8H11BrN2 216.00851。
实施例2中间体化合物2(3,5,6-三甲基吡嗪-2-羧酸)的制备
按照“《新型川芎嗪衍生物的合成及其抗癌活性研究》.西北药学杂志,29(1):58-64”方法制备。将10.0g(73.53mmol)川芎嗪混悬于100.0mL的蒸馏水中,称取11.62g(73.53mmol)高锰酸钾,分3批加入,37℃,磁力搅拌24h。将上述混合液冷却,抽滤,滤液用360mg·L-1的盐酸调pH至1~2,然后用乙酸乙酯萃取3次,收集乙酸乙酯层并用无水硫酸钠干燥,减压浓缩至干,丙酮重结晶,得到白色固体,收率:47.8%,m.p.:162-163℃。
实施例3中间体化合物4(3β-羟基齐墩果-12-烯-28-酸-苄酯)的制备
将2.28g(5mmol)齐墩果酸,0.855g(5mmol)苄基溴溶解于25mLN,N-二甲基甲酰胺(DMF)中,然后加入0.691g(5mmol)无水碳酸钾,于85℃油浴中反应,磁力搅拌2h;反应液冷却至室温后,将反应液加入适量饱和食盐水分散,然后用等体积乙酸乙酯萃取2次,收集乙酸乙酯层并用无水硫酸钠干燥,减压回收溶剂,得到化合物4的粗品。
White amorphous solid,m.p.:188.8-189.5℃,yield 95.8%.1H-NMR(CDCl3)(ppm):0.63,0.80,0.90,0.92,0.94,1.00,1.15(s,each,3H,7×-CH3),2.92(m,1H),3.23(m,1H),5.06,5.12,(d,J=12.4Hz,1H,-CH2),5.31(t,J=3.6Hz,1H,=CH-),7.36(m,5H,Ar-H),1.00-2.50(23H,methyl-and methylene-of triterpenoid structure).
实施例4中间体化合物5的合成
将2.283g(5mmol)熊果酸,0.855g(5mmol)苄基溴溶解于25mL N,N-二甲基甲酰胺(DMF)中,然后加入0.691g(5mmol)无水碳酸钾,于85℃油浴中反应,磁力搅拌2h;反应液冷却至室温后,将反应液加入适量饱和食盐水分散,然后用等体积乙酸乙酯萃取2次,收集乙酸乙酯层并用无水硫酸钠干燥,减压回收溶剂,得到化合物5的粗品。
White powder,m.p.:76.8-77.4℃,yield 92.7%.1H-NMR(CDCl3)(ppm):0.67,0.80,0.87(d,J=6.0Hz,3H,3×-CH3),0.92,0.96(d,J=6.0Hz,3H,2×-CH3),1.01,1.10(s,3H,2×-CH3),2.28(d,J=11.2Hz,1H),3.23(m,1H),5.01,5.13(d,each,J=12.4Hz,1H,-CH2),5.26(t,J=3.6Hz,1H,=CH-),7.36(m,5H,Ar-H),1.00-2.50(24H,methyl-and methylene-oftriterpenoid structure).
实施例5中间体化合物6的合成
将2.353g(5mmol)甘草次酸,0.855g(5mmol)苄基溴溶解于25mlN,N-二甲基甲酰胺(DMF)中,然后加入0.691g(5mmol)无水碳酸钾,于85℃油浴中反应,磁力搅拌2h;反应液冷却至室温后,将反应液加入适量饱和食盐水分散,然后用等体积乙酸乙酯萃取2次,收集乙酸乙酯层并用无水硫酸钠干燥,减压回收溶剂,得到化合物6的粗品。
White powder,m.p.:92.9-93.7℃,yield 94.1%.1H-NMR(CDCl3)(ppm):0.76,0.83,1.02,1.13,1.16,1.18,1.37(s,each,3H,7×-CH3),3.24(m,1H),5.11,5.22(each,d,J=12.4Hz,1H,-CH2),5.58(s,1H,=CH-),7.39(m,5H,Ar-H),1.00-3.00(22H,methyl-and methylene-of triterpenoid structure).
实施例6中间体化合物7的合成
将2.283g(5mmol)白桦脂酸,0.855g(5mmol)苄基溴溶解于25mlN,N-二甲基甲酰胺(DMF)中,然后加入0.691g(5mmol)无水碳酸钾,于85℃油浴中反应,磁力搅拌2h;反应液冷却至室温后,将反应液加入适量饱和食盐水分散,然后用等体积乙酸乙酯萃取2次,收集乙酸乙酯层并用无水硫酸钠干燥,减压回收溶剂,得到化合物7的粗品。
White powder,m.p.:191.3-192.1℃,yield 92.7%.1H-NMR(CDCl3)(ppm):0.78(brs,6H,2×-CH3),0.82,0.97,0.98,1.70(s,each,3H,4×-CH3),3.05(brs,1H),3.19(m,1H),4.62,4.75(brs,1H,=CH2),5.11,5.17(each,d,J=12.4Hz,1H,-CH2),7.38(m,5H,Ar-H),1.00-2.50(23H,methyl-and methylene-oftriterpenoid structure).
实施例7化合物TBA-X1的合成
将2.28g(5mmol)齐墩果酸,1.08g(5mmol)化合物1溶解于25mLN,N-二甲基甲酰胺(DMF)中,然后加入0.691g(5mmol)无水碳酸钾,于85℃油浴中反应,磁力搅拌1.5h;反应液冷却至室温后,将反应液加入适量饱和食盐水分散,然后用等体积乙酸乙酯萃取2次,收集乙酸乙酯层并用无水硫酸钠干燥,减压回收溶剂,硅胶柱分离(V(石油醚)∶V(乙酸乙酯)=3∶2),乙酸乙酯重结晶得化合物TBA-X1。
White solid,m.p.:185.9-186.6℃,yield 57.0%.1H-NMR(CDCl3)(ppm):0.55,0.80,0.90,0.91,0.93,1.00,1.13(s,each,3H,7×CH3),3.23(m,1H),2.89(m,1H),5.26(brs,1H),5.24,5.14(ea,d,J=12.5Hz,1H,CH2-),2.58(s,3H,CH3),2.54(s,3H,CH3),2.52(s,3H,CH3),1.00-2.50(23H,methyl-andmethylene-of triterpenoid structure).13C-NMR(CDCl3)(ppm):38.4,27.2,79.0,38.8,55.2,18.3,33.1,39.2,47.6,37.0,23.7,122.5,143.6,41.7,27.6,23.1,46.9,41.3,45.9,30.7,33.9,32.7,28.1,15.6,15.3,16.8,25.9,177.2,32.4,23.4;pyrazine ring:64.8,150.9,145.5,148.9,149.1,21.6,21.4,20.5.HRMS(ESI)m/z:591.6581[M+H]+,calcd.for C38H59N2O3 591.4526.
实施例8化合物TBA-X2的合成
将2.283g(5mmol)熊果酸,1.08g(5mmol)化合物1溶解于25mLN,N-二甲基甲酰胺(DMF)中,然后加入0.691mg(5mmol)无水碳酸钾,于85℃油浴中反应,磁力搅拌1.5h;反应液冷却至室温后,将反应液加入适量饱和食盐水分散,然后用等体积乙酸乙酯萃取2次,收集乙酸乙酯层并用无水硫酸钠干燥,减压回收溶剂,硅胶柱分离[V(石油醚)∶V(丙酮)=10∶1]得化合物TBA-X2。
White solid,m.p.:125.9-126.7℃,yield 55.7%.1H-NMR(CDCl3)(ppm):0.60,0.80,0.91,1.00,1.01(s,each,3H,5×-CH3),0.85(d,J=6.5Hz,3H,-CH3),0.95(d,J=6.5Hz,3H,-CH3),2.26(d,J=11.5Hz,1H),2.51(s,3H,-CH3),2.53(s,3H,-CH3),2.58(s,3H,-CH3),3.23(m,1H),5.20(brs,1H,=CH-),5.25,5.06(each,d,J=12.0Hz,1H,-CH2),1.00-2.50(23H,methyl-and methylene-of triterpenoid structure).13C-NMR(CDCl3)(ppm):15.4,15.6,17.0,18.3,21.1,23.2,23.5,24.3,27.3,28.0,28.1,30.7,33.0,36.7,37.0,38.7,38.8,38.8,39.1,39.5,42.0,47.5,48.3,52.9,55.2,79.0,125.7,138.0,176.9(-COO-);pyrazine ring:20.6(-CH3),21.4(-CH3),21.7(-CH3),64.8(-CH2),145.4,148.8,149.3,151.0.HRMS(ESI)m/z:591.45245[M+H]+,calcd.for C38H58N2O3 590.44474.
实施例9化合物TBA-X3的合成
将2.353g(5mmol)甘草次酸,1.08g(5mmol)化合物1溶解于25mlN,N-二甲基甲酰胺(DMF)中,然后加入0.691g(5mmol)无水碳酸钾,于85℃油浴中反应,磁力搅拌1.5h;反应液冷却至室温后,将反应液加入适量饱和食盐水分散,然后用等体积乙酸乙酯萃取2次,收集乙酸乙酯层并用无水硫酸钠干燥,减压回收溶剂,硅胶柱分离[V(石油醚)∶V(丙酮)=10∶1],丙酮重结晶得化合物TBA-X3。
Colorless crystals,m.p.:225.7-226.5℃,yield 53.0%.1H-NMR(CDCl3)(ppm):0.81,0.82,1.01,1.13,1.14,1.20,1.36(s,each,3H,7×CH3),3.23(m,1H,H-3),5.55(s,1H),5.27,5.19(ea,d,J=12.5Hz,1H,CH2-),2.55(s,3H,CH3-),2.54(s,3H,CH3-),2.52(s,3H,CH3-),1.00-3.00(22H,methyl-andmethylene-of triterpenoid structure).13C-NMR(CDCl3)(ppm):39.2,27.3,78.8,39.2,55.0,17.5,32.8,43.2,61.8,37.1,200.0,128.6,168.9,45.4,26.5,26.4,31.9,48.0,41.1,44.2,31.2,37.7,28.5,15.6,16.4,18.7,23.4,28.1,28.5,176.1;pyrazine ring:64.7,151.1,145.0,148.4,149.3,21.5,21.5,20.4.HRMS(ESI)m/z:605.5377[M+H]+,calcd.for C38H57N2O4 605.4318.
实施例10化合物TBA-X4的合成
将2.283g(5mmol)白桦脂酸,1.08g(5mmol)化合物1溶解于25mlN,N-二甲基甲酰胺(DMF)中,然后加入0.691g(5mmol)无水碳酸钾,于85℃油浴中反应,磁力搅拌1.5h;反应液冷却至室温后,将反应液加入适量饱和食盐水分散,然后用等体积乙酸乙酯萃取2次,收集乙酸乙酯层并用无水硫酸钠干燥,减压回收溶剂,硅胶柱分离[V(石油醚)∶V(丙酮)=10∶1]得化合物TBA-X4。
White powder,m.p.:184.6-185.4℃,yield 54.1%.1H-NMR(CDCl3)(ppm):0.78,0.80,0.82,0.96,0.98,1.69(s,each,3H,6×-CH3),2.51(s,3H,-CH3),2.53(s,3H,-CH3),2.57(s,3H,-CH3),3.02(m,1H),3.19(m,1H),4.61,4.74(each,brs,1H,=CH2),5.20,5.23(each,d,J=12.5Hz,1H,-CH2),1.00-2.50(25H,methyl-and methylene-of triterpenoid structure).13C-NMR(CDCl3)(ppm):14.7,15.4,15.9,16.1,18.3,19.4,20.9,25.5,27.4,28.0,29.7,30.6,32.1,34.4,36.9,37.2,38.1,38.7,38.9,40.7,42.4,46.9,49.5,50.6,55.4,56.7,79.0,109.6,150.5,175.5(-COO-);pyrazine ring:20.4(-CH3),21.4(-CH3),21.6(-CH3),64.3(-CH2),145.4,148.7,148.9,150.9.HRMS(ESI)m/z:591.45212[M+H]+,calcd.for C38H58N2O3 590.44474.
实施例11化合物TBA-X5的合成
将591.45mg(1mmol)TBA-X1,199.32mg(1.2mmol)化合物2,287.55mg(1.5mmol)EDCI,12.2mg(0.1mmol)DMAP依次加入圆底烧瓶中;再加入20mL二氯甲烷,常温搅拌反应12h,TLC检测反应基本完全。将反应液加入适量饱和食盐水分散,然后用等体积乙酸乙酯萃取2次,收集乙酸乙酯层并用无水硫酸钠干燥,减压回收溶剂,硅胶柱分离[V(石油醚)∶V(丙酮)=7∶1]得化合物TBA-X5。
White powder,m.p.:193.0-193.7℃,yield 53.7%.1H-NMR(CDCl3)(ppm):0.59,0.92,0.93,0.97,1.15(s,each,3H,5×-CH3),0.98(brs,6H,2×-CH3),2.52(s,3H,-CH3),2.53(s,3H,-CH3),2.58(brs,9H,3×-CH3),2.73(s,3H,-CH3),2.89(m,1H),4.87(m,1H),5.18,5.24,(each,d,J=12.5Hz,1H,-CH2),5.27(brs,1H,=CH-),1.00-2.50(22H,methyl-and methylene-of triterpenoidstructure).13C-NMR(CDCl3)(ppm):15.4,16.8,17.0,18.2,23.1,23.4,23.7,25.8,27.6,28.2,30.7,32.4,32.7,33.1,33.9,37.0,38.0,38.2,39.3,41.4,41.7,45.9,46.9,47.5,55.4,82.9,122.4,143.7,177.2(-COO-);pyrazine ring:20.5(-CH3),21.4(-CH3),21.6(-CH3),22.1(-CH3),22.7(-CH3),64.9(-CH2),140.8,145.5,148.8,149.1,149.3,149.9,150.9,153.8,166.2(-COO-),HRMS(ESI)m/z:761.49756[M+Na]+,calcd.for C46H66N4O4 738.50841.
实施例12化合物TBA-X6的合成
将590.44mg(1mmol)TBA-X2,199.32mg(1.2mmol)化合物2,287.55mg(1.5mmol)EDCI,12.2mg(0.1mmol)DMAP依次加入圆底烧瓶中;再加入20mL二氯甲烷,常温搅拌反应12h,TLC检测反应基本完全。将反应液加入适量饱和食盐水分散,然后用等体积乙酸乙酯萃取2次,收集乙酸乙酯层并用无水硫酸钠干燥,减压回收溶剂,硅胶柱分离[V(石油醚)∶V(丙酮)=7∶1]得化合物TBA-X6。
White solid,m.p.:168.2-168.9℃,yield 46.8%.1H-NMR(CDCl3)(ppm):0.62,0.98,1.09(s,each,3H,3×-CH3),0.87(d,J=6.0Hz,3H,-CH3),0.96(d,J=6.0Hz,3H,-CH3),0.99(brs,6H,2×-CH3),2.26(d,J=11.5Hz,1H),2.52(s,3H,-CH3),2.54(s,3H,-CH3),2.57(brs,9H,-CH3),2.73(s,3H,-CH3),4.87(m,1H),5.06(each,d,J=12.0Hz,1H,-CH2),5.21(brs,1H,=CH-),5.25,1.00-2.50(22H,methyl-and methylene-of triterpenoidstructure).13C-NMR(CDCl3)(ppm):15.5,17.0,17.0,17.1,18.2,21.2,23.2,23.5,23.7,24.2,27.9,28.2,30.7,33.0,36.7,36.9,38.0,38.4,38.8,39.1,39.6,42.0,47.5,48.3,52.9,55.4,83.0,125.6,138.1,177.0(-COO-);pyrazine ring:20.5(-CH3),21.4(-CH3),21.6(-CH3),22.1(-CH3),22.7(-CH3),64.8(-CH2),140.8,145.5,148.9,149.2,149.3,149.9,150.9,153.8,166.2(-COO-).HRMS(ESI)m/z:739.51645[M+H]+,calcd.for C46H66N4O4 738.50841.
实施例13化合物TBA-X7的合成
将605.43mg(1mmol)TBA-X3,199.32mg(1.2mmol)化合物2,287.55mg(1.5mmol)EDCI,12.2mg(0.1mmol)DMAP依次加入圆底烧瓶中;再加入20mL二氯甲烷,常温搅拌反应12h,TLC检测反应基本完全。将反应液加入适量饱和食盐水分散,然后用等体积乙酸乙酯萃取2次,收集乙酸乙酯层并用无水硫酸钠干燥,减压回收溶剂,硅胶柱分离[V(石油醚)∶V(丙酮)=7∶1]得化合物TBA-X7。
White powder,m.p.:295.9-296.7℃,yield 51.7%.1H-NMR(CDCl3)(ppm):0.82,1.00,1.01,1.15,1.39(s,each,3H,5×-CH3),1.22(brs,6H,2×-CH3),2.53(s,3H,-CH3),2.54(s,3H,-CH3),2.56(s,3H,-CH3),2.58(brs,6H,2×-CH3),2.73(s,3H,-CH3),4.89(m,1H),5.20,5.28(each,d,J=15.0Hz,1H,-CH2),5.58(s,1H,=CH-),1.00-3.00(21H,methyl-and methylene-of triterpenoidstmcture).13C-NMR(CDCl3)(ppm):16.4,17.0,17.4,18.7,23.4,23.7,26.5,26.5,28.2,28.4,28.5,31.2,31.9,32.7,37.0,37.7,38.4,38.9,41.1,43.2,44.2,45.4,48.1,55.1,61.7,82.6,128.5,169.0,199.8(-C=O),176.1(-COO-);pyrazine ring:20.5(-CH3),21.4(-CH3),21.6(-CH3),22.1(-CH3),22.6(-CH3),64.7(-CH2),140.8,145.0,148.4,149.2,150.0,149.3,151.1,153.8,166.2(-COO-).HRMS(ESI)m/z:775.47629[M+Na]+,calcd.for C46H64N4O5 752.48767.
实施例14化合物TBA-X8的合成
将590.44mg(1mmol)TBA-X4,199.32mg(1.2mmol)化合物2,287.55mg(1.5mmol)EDCI,12.2mg(0.1mmol)DMAP依次加入圆底烧瓶中;再加入20mL二氯甲烷,常温搅拌反应12h,TLC检测反应基本完全。将反应液加入适量饱和食盐水分散,然后用等体积乙酸乙酯萃取2次,收集乙酸乙酯层并用无水硫酸钠干燥,减压回收溶剂,硅胶柱分离[V(石油醚)∶V(丙酮)=7∶1]得化合物TBA-X8。
White powder,m.p.:142.1-142.9℃,yield 47.9%.1H-NMR(CDCl3)(ppm):0.82,0.89,0.98,1.70(s,each,3H,4×-CH3),0.96(brs,6H,2×-CH3),2.51(s,3H,-CH3),2.53(s,3H,-CH3),2.57(brs,9H,3×-CH3),2.72(s,3H,-CH3),3.02(m,1H),4.62,4.74(each,brs,1H,=CH2),4.84(m,1H),5.23,5.20(each,d,J=12.5Hz,1H,-CH2),1.00-2.50(24H,methyl-and methylene-of triterpenoidstructure).13C-NMR(CDCl3)(ppm):14.7,15.9,16.2,16.8,18.2,19.3,20.9,23.8,25.5,28.1,29.6,30.6,32.1,34.3,36.9,37.2,38.1,38.5,40.7,42.4,46.9,49.5,50.5,55.5,56.7,83.0,109.7,150.5,175.4(-COO-);pyrazine ring:20.5(-CH3),21.4(-CH3),21.6(-CH3),21.6(-CH3),22.1(-CH3),22.6(-CH3),64.3(-CH2),140.9,145.4,148.7,148.9,149.3,149.9,150.9,153.7,166.2(-COO-).HRMS(ESI)m/z:739.51637[M+H]+,calcd.for C46H66N4O4 738.50841.
实施例15化合物TBA-X9的合成
将1.64g(3mmol)化合物4,581.60mg(3.5mmol)化合物2,670.95mg(3.5mmol)EDCI,36.65mg(0.3mmol)DMAP依次加入圆底烧瓶中;再加入20mL二氯甲烷,常温搅拌反应12h,TLC检测反应基本完全。将反应液加入适量饱和食盐水分散,然后用等体积乙酸乙酯萃取2次,收集乙酸乙酯层并用无水硫酸钠干燥,减压回收溶剂,硅胶柱分离[V(石油醚)∶V(丙酮)=8∶1]得化合物TBA-X9。
White powder,m.p.:194.2-194.9℃,yield 47.9%.1H-NMR(CDCl3)(ppm):0.85,0.92,0.95,0.97,0.98,0.98,1.17(s,each,3H,7×-CH3),2.58(brs,6H,2×-CH3),2.74(s,3H,-CH3),2.89(m,1H),4.87(m,1H),5.07,5.12(each,d,J=13.0Hz,1H,-CH2),5.32(brs,1H,=CH-),7.35(m,5H,Ar-H),1.00-2.50(22H,methyl-and methylene-of triterpenoid structure).13C-NMR(CDCl3)(ppm):15.4,16.9,17.0,18.3,23.1,23.4,23.7,25.9,27.6,28.2,30.7,32.4,32.7,33.1,33.9,37.0,38.0,38.2,39.4,41.4,41.7,45.9,46.8,47.6,55.4,83.0,122.4,127.9,128.0,128.4,136.5,143.8,177.4(-COO-);pyrazine ring:21.6(-CH3),22.0(-CH3),22.6(-CH3),65.9(-CH2),140.9,149.4,149.9,153.7,166.2(-COO-).HRMS(ESI)m/z:717.46027[M+Na]+,calcd.for C45H62N2O4 694.47096.
实施例16化合物TBA-X10的合成
将1.64g(3mmol)化合物5,581.60mg(3.5mmol)化合物2,670.95mg(3.5mmol)EDCI,36.65mg(0.3mmol)DMAP依次加入圆底烧瓶中;再加入20mL二氯甲烷,常温搅拌反应12h,TLC检测反应基本完全。将反应液加入适量饱和食盐水分散,然后用等体积乙酸乙酯萃取2次,收集乙酸乙酯层并用无水硫酸钠干燥,减压回收溶剂,硅胶柱分离[V(石油醚)∶V(丙酮)=8∶1]得化合物TBA-X10。
White solid,m.p.:218.5-219.3℃,yield 51.1%.1H-NMR(CDCl3)(ppm):0.89(d,J=6.5Hz,3H,-CH3),0.98(brs,12H,4×-CH3),0.68,1.12(s,each,3H,2×-CH3),2.29(d,J=11.5Hz,1H),2.58(brs,6H,2×-CH3),2.74(s,3H,-CH3),4.87(m,1H),5.10,5.13(each,d,J=12.5Hz,1H,-CH2),5.27(brs,1H,=CH-),7.35(m,5H,Ar-H),1.00-2.50(22H,methyl-and methylene-of triterpenoidstmcture).13C-NMR(CDCl3)(ppm):15.5,17.0,17.1,18.2,21.2,23.3,23.6,23.7,24.3,28.0,28.2,30.7,33.0,36.7,36.9,38.0,38.4,38.9,39.1,39.6,42.1,47.5,48.1,52.9,55.4,83.0,125.6,127.9,128.2,128.4,136.4,138.2,177.3(-COO-);pyrazine ring:21.6(-CH3),22.0(-CH3),22.6(-CH3),66.0(-CH2),140.9,149.4,149.9,153.7,166.2(-COO-).HRMS(ESI)m/z:717.46082[M+Na]+,calcd.forC45H62N2O4 694.47096.
实施例17化合物TBA-X11的合成
将1.68g(3mmol)化合物6,581.60mg(3.5mmol)化合物2,670.95mg(3.5mmol)EDCI,36.65mg(0.3mmol)DMAP依次加入圆底烧瓶中;再加入20mL二氯甲烷,常温搅拌反应12h,TLC检测反应基本完全。将反应液加入适量饱和食盐水分散,然后用等体积乙酸乙酯萃取2次,收集乙酸乙酯层并用无水硫酸钠干燥,减压回收溶剂,硅胶柱分离[V(石油醚)∶V(丙酮)=8∶1]得化合物TBA-X11。
White powder,m.p.:212.3-213.0℃,yield 49.2%.1H-NMR(CDCl3)(ppm):0.76,1.00,1.01,1.14,1.19,1.22,1.39(s,each,3H,7×-CH3),2.58(brs,6H,2×-CH3),2.74(s,3H,-CH3),4.89(m,1H),5.11,5.23(each,d,J=10.0Hz,1H,-CH2),5.58(s,1H,=CH-),7.38(m,5H,Ar-H),1.00-3.00(21H,methyl-and methylene-of triterpenoid structure).13C-NMR(CDCl3)(ppm):16.4,17.0,17.4,18.7,23.3,23.7,26.4,26.5,28.2,28.3,28.4,31.2,31.8,32.7,37.0,37.7,38.4,38.9,41.1,43.2,44.0,45.4,48.3,55.1,61.7,82.6,128.2,128.3,128.5,128.6,136.2,169.1,176.2(-COO-),199.9(-C=O);pyrazinering:21.6(-CH3),22.0(-CH3),22.6(-CH3),66.2(-CH2),140.8,149.3,149.9,153.7,166.2(-COO-).HRMS(ESI)m/z:731.44060[M+Na]+,calcd.forC45H60N2O5 708.45022.
实施例18化合物TBA-X12的合成
将1.64g(3mmol)化合物7,581.60mg(3.5mmol)化合物2,670.95mg(3.5mmol)EDCI,36.65mg(0.3mmol)DMAP依次加入圆底烧瓶中;再加入20mL二氯甲烷,常温搅拌反应12h,TLC检测反应基本完全。将反应液加入适量饱和食盐水分散,然后用等体积乙酸乙酯萃取2次,收集乙酸乙酯层并用无水硫酸钠干燥,减压回收溶剂,硅胶柱分离[V(石油醚)∶V(丙酮)=8∶1]得化合物TBA-X12。
White powder,m.p.:162.1-162.8℃,yield 49.0%.1H-NMR(CDCl3)(ppm):0.80,0.89,0.98,1.71(s,each,3H,4×-CH3),0.96(brs,6H,2×-CH3),2.58(brs,6H,2×-CH3),2.73(s,3H,-CH3),3.04(m,1H),4.63(brs,1H,=CH2),4.75(brs,1H),4.84(m,1H),5.12,5.17(each,d,J=12.5Hz,1H,-CH2),7.38(m,5H,Ar-H),1.00-2.50(24H,methyl-and methylene-oftriterpenoid structure).13C-NMR(CDCl3)(ppm):14.7,15.9,16.2,16.8,18.2,19.4,21.0,23.8,25.5,28.1,29.6,30.6,32.1,34.3,36.9,37.2,38.1,38.2,38.5,40.7,42.4,47.0,49.5,50.5,55.5,56.7,83.0,109.6,128.1,128.3,128.5,136.5,150.5,175.8(-COO-);pyrazine ring:21.6(-CH3),22.0(-CH3),22.6(-CH3),65.7(-CH2),140.9,149.3,149.9,153.7,166.2(-COO-).HRMS(ESI)m/z:717.46016[M+Na]+,calcd.for C45H62N2O4 694.47096.
实施例19化合物TBA-X13的合成
将694.47mg(1mmol)TBA-X9溶于30ml甲醇中,再加入80mg10%Pd(OH)2/C常温搅拌反应12h,TLC检测反应基本完全。将反应液过滤,滤液减压回收溶剂,硅胶柱分离[V(石油醚)∶V(丙酮)=5∶1]得化合物TBA-X13。
White powder,m.p.:289.7-290.5℃,yield 92.8%.1H-NMR(CDCl3)(ppm):0.80,0.94,0.96,0.98,0.99,1.00,1.18(s,each,3H,7×-CH3),2.57(brs,6H,2×-CH3),2.73(s,3H,-CH3),2.86(m,1H),4.87(m,1H),5.31(brs,1H,=CH-),1.00-2.50(23H,methyl-and methylene-of triterpenoidstructure).13C-NMR(CDCl3)(ppm):15.4,17.0,17.2,18.2,22.9,23.4,23.6,23.7,25.9,27.7,28.2,30.7,32.5,32.6,33.1,33.8,37.0,38.0,38.2,39.3,41.0,41.6,45.9,46.5,47.6,55.4,83.0,122.5,143.7,183.4(-COOH);pyrazine ring:21.6(-CH3),22.0(-CH3),22.6(-CH3),140.8,149.3,149.9,153.8,166.2(-COO-).HRMS(ESI)m/z:627.41275[M+Na]+,calcd.for C38H56N2O4604.42401.
实施例20化合物TBA-X14的合成
将694.47mg(1mmol)TBA-X10溶于30ml甲醇中,再加入80mg10%Pd(OH)2/C常温搅拌反应12h,TLC检测反应基本完全。将反应液过滤,滤液减压回收溶剂,硅胶柱分离[V(石油醚)∶V(丙酮)=5∶1]得化合物TBA-X14。
White solid,m.p.:305.9-306.6℃,yield 90.6%.1H-NMR(CDCl3)(ppm):0.81,1.02,1.12(s,each,3H,3×-CH3),0.89(d,J=6.5Hz,3H,-CH3),0.98(brs,9H,3×-CH3),2.22(d,J=11.0Hz,1H),2.58(brs,6H,2×-CH3),2.73(s,3H,-CH3),4.87(m,1H),5.27(brs,1H,=CH-),1.00-2.50(23H,methyl-andmethylene-of triterpenoid structure).13C-NMR(CDCl3)(ppm):15.6,17.0,17.1,18.2,21.2,23.3,23.6,23.7,24.1,28.0,28.2,30.6,32.9,36.7,37.0,38.0,38.4,38.8,39.0,39.6,42.0,47.5,48.0,52.6,55.4,83.0,125.7,138.0,183.4(-COOH);pyrazine ring:21.6(-CH3),22.0(-CH3),22.6(-CH3),140.9,149.4,149.9,153.7,166.2(-COO-).HRMS(ESI)m/z:627.41319[M+Na]+,calcd.for C38H56N2O4604.42401.
实施例20化合物TBA-X15的合成
将708.45mg(1mmol)TBA-X11溶于30ml甲醇中,再加入80mg10%Pd(OH)2/C常温搅拌反应12h,TLC检测反应基本完全。将反应液过滤,滤液减压回收溶剂,硅胶柱分离[V(石油醚)∶V(丙酮)=5∶1]得化合物TBA-X15。
White powder,m.p.:305.4-306.2℃,yield 90.1%.1H-NMR(CDCl3)(ppm):0.87,1.00,1.01,1.17,1.23,1.26,1.42(s,each,3H,7×-CH3),2.58(brs,6H,2×-CH3),2.74(s,3H,-CH3),4.90(m,1H),5.75(s,1H,=CH-),1.00-3.00(22H,methyl-and methylene-of triterpenoid structure).13C-NMR(CDCl3)(ppm):16.4,17.0,17.4,18.7,23.3,23.7,26.5,26.5,28.2,28.4,28.6,31.0,31.9,32.7,37.0,37.7,38.4,38.9,40.9,43.3,43.8,45.5,48.3,55.1,61.7,82.7,128.5,169.4,181.3(-COOH),200.2(-C=O);pyrazine ring:21.5(-CH3),22.0(-CH3),22.5(-CH3),140.9,149.4,149.9,153.7,166.1(-COO-).HRMS(ESI)m/z:617.39564[M-H]-,calcd.for C38H54N2O5 618.40327.
实施例21化合物TBA-X16的合成
将694.47mg(1mmol)TBA-X12溶于30ml甲醇中,再加入80mg10%Pd(OH)2/C常温搅拌反应12h,TLC检测反应基本完全。将反应液过滤,滤液减压回收溶剂,硅胶柱分离[V(石油醚)∶V(丙酮)=5∶1]得化合物TBA-X16。
White powder,m.p.:279.5-280.3℃,yield 89.2%.1H-NMR(CDCl3)(ppm):0.91,0.96,0.97,0.98,1.02,1.72(s,each,3H,6×-CH3),2.57(brs,6H,2×-CH3),2.72(s,3H,-CH3),3.04(m,1H),4.64,4.77(each,brs,1H,=CH2),4.85(m,1H),1.00-2.50(25H,methyl-and methylene-of triterpenoid structure).13C-NMR(CDCl3)(ppm):14.7,16.1,16.2,16.8,18.2,19.4,20.9,23.8,25.5,28.1,29.7,30.6,32.2,34.3,37.1,37.2,38.2,38.4,38.5,40.8,42.5,47.0,49.3,50.5,55.5,56.4,83.0,109.7,150.4,181.4(-COOH);pyrazine ring:21.6(-CH3),22.0(-CH3),22.6(-CH3),140.9,149.3,149.9,153.7,166.2(-COO-).HRMS(ESI)m/z:627.41288[M+Na]+,calcd.for C38H56N2O4 604.42401.
实施例22
取实施例7~21任一制备的化合物10g,加入注射剂(包括冻干粉针剂和无菌分装干粉针剂)适当辅料,按注射剂(包括冻干粉针剂和无菌分装干粉针剂)工艺制备成抗肿瘤药注射剂。
实施例23
取取实施例7~21任一制备的化合物10g,加入片剂(包括缓控释片、骨架片、包衣片、分散片等)适当辅料,按片剂(包括缓控释片、骨架片、包衣片、分散片等)工艺制备成抗肿瘤药片剂。
实施例24
取取实施例7~21任一制备的化合物10g,加入胶囊剂适当辅料,按胶囊剂工艺制备成抗肿瘤药胶囊剂。
实施例25
取取实施例7~21任一制备的化合物10g,加入乳剂(包括微乳、纳米乳等)适当辅料,按乳剂(包括微乳、纳米乳等)工艺制备成抗肿瘤药乳剂。
实施例26
取取实施例7~21任一制备的化合物10g,加入颗粒剂适当辅料,按颗粒剂工艺制备成抗肿瘤药颗粒剂。
实施例27
取取实施例7~21任一制备的化合物10g,加入缓释控释剂适当辅料,按缓释控释剂工艺制成抗肿瘤药缓释控释剂。
实施例28
取取实施例7~21任一制备的化合物10g,加入口服液适当辅料,按口服液工艺制备成抗肿瘤药口服液。
实施例29
取取实施例7~21任一制备的化合物10g,加入脂质体剂型适当辅料,按脂质体工艺制备成抗肿瘤药脂质体剂型。